GlobeNewswire Inc | Feb 16, 2021 04:01PM EST

February 16, 2021

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the Company) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm EDT.

The live call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (International). The passcode for the conference call is 13715482. The live webcast may be accessed using the link here, or by visiting the Investors section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Companys website for approximately 90 days after the call.

Additionally, the Company announced today that management will host a virtual R&D Day on Thursday, March 11, 2021 at 11:00am EDT. Details for the R&D Day event, including the agenda and guest speakers, will be discussed during the fourth quarter conference call.

AboutZiopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viralSleeping Beautygene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufacturedSleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with theNational Cancer Institute,The University of Texas MD Anderson Cancer Centerand Regeneron Pharmaceuticals. For more information, please visitwww.ziopharm.com.

Investor Relations Contact:Adam D. Levy, Ph.D., MBAEVP, Investor Relations and Corporate CommunicationsT: 508.552.9255E:alevy@ziopharm.com

Media Relations Contact:Patrick BurseyLifeSci CommunicationsT: 646.876.4932E: pbursey@lifescicomms.com